玻璃体内注射贝伐单抗对角膜内皮细胞的影响：一项体内评估。
Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation.
机构信息
Ophthalmology Clinic, Faculty of Medicine, Cairo University, Giza, Egypt.
出版信息
J Ocul Pharmacol Ther. 2009 Dec;25(6):513-7. doi: 10.1089/jop.2009.0056.
BACKGROUND
We studied the effect of an intracameral bevacizumab injection on the corneal endothelium and iris neovessels (INV).
METHODS
Ten eyes were studied in 10 patients with an average age of 52.1 +/- 13.17 years. Patients underwent intracameral bevacizumab injections at a concentration of 1.25 mg/0.05 mL. Intraocular pressure, best-corrected visual acuity, gonioscopy, neovascular membrane extent, anterior segment photography, iris fluorescein angiography, pachymetry, and specular microscopy were recorded preoperatively and postoperatively.
RESULTS
The minimum follow-up period was 4 months. INVs started to regress within the first 2 days after the injection and regressed completely by the end of the fourth week. Reduction in INV leakage started 1 week after injection, and resolved in 8 eyes (80%) by the end of the fourth week. Intraocular pressure dropped significantly from 17.8 +/- 4.8 mmHg to 16.6 +/- 2.8 mmHg over 4 weeks. The mean endothelial cell loss was 3.95% +/- 6.78%.
CONCLUSIONS
An intracameral bevacizumab injection proved to be safe for corneal endothelial cells.
背景
我们研究了前房内注射贝伐单抗对角膜内皮和虹膜新生血管（INV）的影响。
方法
10 例患者（10 只眼）的平均年龄为 52.1 +/- 13.17 岁。患者接受浓度为 1.25 mg/0.05 mL 的前房内贝伐单抗注射。记录术前和术后眼压、最佳矫正视力、房角镜检查、新生血管膜范围、眼前段照相、虹膜荧光血管造影、角膜厚度和共焦显微镜检查结果。
结果
最短随访时间为 4 个月。INV 在注射后第 2 天开始消退，第 4 周末完全消退。INV 渗漏减少在注射后 1 周开始，并在第 4 周末 8 只眼（80%）缓解。眼压在 4 周内从 17.8 +/- 4.8mmHg 降至 16.6 +/- 2.8mmHg。平均内皮细胞丢失率为 3.95% +/- 6.78%。
结论
前房内注射贝伐单抗对角膜内皮细胞安全有效。
Zotero 插件